补肺抗癌汤对中晚期非小细胞肺癌疗效的研究中西医结合;临床专业论文.docxVIP

PAGE PAGE 10 中 文 摘 要 目的 ：观察吉非替尼对晚期非小细胞肺癌的治疗与补肺抗癌汤配合吉非 替尼对非小细胞肺癌的治疗后疗效对比。 方法 ：选用 40 名晚期非小细胞肺癌病人进行治疗后对比。运用简单随 尼对肺癌的治疗，一月为一疗程；对照组吉非替尼口服，一月为一疗程， 两组均以一疗程为观察期，治疗后依据两个标准评定：①WHO 肿瘤治疗 客观效果判定标准进行评价，分为完全缓解(CR)、部分缓解(PR)、无变 化(NC)和病情恶化(PD)，以 CR+PR 为有效。②生活质量评定：依据 KPS 评分，治疗前后计分增加≥10 分为提高，降低≥10 分为降低，变化在 10 分以内为稳定。临床研究的数据资料采用 SPSS 16.0 数据软件包处理统计 软件进行分析处理。 结果 ：治疗组与对照组治疗后依据 WHO 肿瘤治疗客观效果判定标准评 定，无统计学意义（P＞0.01），治疗组与对照组治疗后依据生活质量评定 有显著性差异（P＜0.01），有临床意义。 结论 ：治疗组与对照组在肿瘤治疗客观效果判定标准评判方面无明显差 异；治疗组的病人能提高食欲、增加体力、改善睡眠、增加效果方面都 有比较好的作用，能明显减轻吉非替尼的副作用，生活质量明显提高， 在生活质量评定方面有明显差异，有临床意义。 关键词 ：肺癌；非小细胞肺癌；吉非替尼；补肺抗癌汤 The lungs cancer soup combined for gefitinib do the study of the middle-late lung cancer treatment Abstract Objective: To investigate gefitinib in advanced NSCLC treatment and lungs soup with gefitinib for NSCLC treatment efficacy of contrast. Methods: After selecting 40 patients with advanced NSCLC after treatment compared. The use of simple treatment for lung cancer with Nigeria, in January for a course; control group oral gefitinib in January for a course, a course for the two groups are observed, treatment and assessment after the basis of two criteria: ①WHO tumor treatment objective effect determination standard to luate the complete remission (CR), partial remission (PR), stable disease (SD) and disease progression (PD), the CR + PR was effective. ② Quality of Life: According to the KPS score after treatment increased ≥ 10 points into enhance, reduce ≥ 10 is divided into lower, change in 10 minutes or less for stability. Clinical research data processing using SPSS 16.0 statistical software package for data analysis and processing. Results: The treatment group and control group after treatment of WHO tumor treatment objective effect determination standard based on recent clinical results, no statistical significance (P 0.01), treatment group and control group based on the quality of life assessment after treatment was significantly different(P0.